Oxlumo

Chemical Namelumasiran
Dosage FormInjection (subcutaneous; 94.5 mg/0.5 mL
Drug ClassOligonucleotides
SystemUrinary
CompanyAlnylam Pharmaceuticals Inc.
Approval Year2020

Indication

  • For the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Oxlumo (lumasiran) Prescribing Information. 2020Alnylam Pharmaceuticals, Inc., Cambridge, MA
Document TitleYearSource
Assessment report: Oxlumo 2020EMA